Samsung Bioepis And Organon Get First High-Concentration Adalimumab Nod In US

Firms Receive First FDA Approval For Higher-Strength 100mg/ml Humira Biosimilar

 
• By Dave Wallace
High low 3D words
Samsung Bioepis and Organon are the first to have both a high- and low-concentration adalimumab biosimilar approved in the US • Source: Shutterstock

More from Biosimilars

More from Products